Compugen Ltd. announced the discovery and experimental verification of CGEN-438, a potential blood based biomarker for lung cancer. CGEN-438 is novel splice variant peptide of delta-like protein 3 precursor (DLL3). Importantly, the Compugen discovered biomarker is a peptide that is

BOSTON -- Medical researchers in Boston say arsenic can be used in conjunction with chemotherapy to treat chronic myeloid leukemia. The research team led by Dr. Pier Paolo Pandolfi , a Harvard Medical School professor and head of the Cancer

HOUSTON -- Oncolin Therapeutics, Inc., announces that its new Super Cell Blocker, ONC-127, has been effective in treating animals that have been implanted with human tumors in their brains. This technology has extended the life of animals in a preclinical

DELAND, Fla., -- USHIFU, LLC, the clinical trial management provider for Focus Surgery, Inc. (Indianapolis, IN), is pleased to announce conditional written approval pending minor changes to the protocol from the FDA to begin a pivotal trial for the treatment

Researchers at Fred Hutchinson Cancer Research Center have a lead role in a new public/private partnership to create the first systematic surveillance program of men with prostate cancer to look for biological clues to help determine when to wait and

Data detailed in 'Higher incidence of abnormal Pap smears in women with inflammatory bowel disease' have been presented. "Immunosuppression results in a higher incidence of cervical dysplasia compared with healthy controls. We examined the relationship between immunomodulator use and the